Research shows that 16-40% of pediatric patients experience residual paralysis or other postoperative complications when anesthesia is managed without objective neuromuscular monitoring. The new guidelines, presented today at the European Society of Pediatric Anesthesia (ESPA) 2025 congress in Berlin by the ESAIC-ESPA Task Force, emphasize the importance of EMG-based monitoring during pediatric anesthesia. This approach ensures accurate dosing of both paralytic and reversal drugs, as well as helps secure timely and safe extubation. In addition, the guidelines specifically highlight EMG-based monitoring for its accuracy and reliability.

“Today’s presentation confirms the pre-announcement made at the Euroanaesthesia congress earlier this year and represents a major milestone for pediatric patient safety. It also opens interesting market opportunities for Senzime, as our TetraGraph system is specifically designed and approved for pediatric patients using the recommended EMG monitoring technique. Pediatric patients have long been underserved when it comes to neuromuscular monitoring, and with more than 10 million major pediatric surgeries performed annually, this is truly a pivotal moment for the youngest and most vulnerable patients”, commented Philip Siberg, CEO of Senzime.

Senzime’s TetraGraph^® neuromuscular monitoring system is already in use at leading pediatric hospitals and holds both CE and FDA clearance for patients from one month of age. TetraGraph was the first portable system to utilize EMG and has since been further refined with proprietary TetraGraph Adaptive Intelligence™, enabling real-time, personalized anesthesia. Unlike legacy monitors, TetraGraph measures the direct effects of paralytic drugs with proven best-in-class accuracy, making it especially well-suited for pediatric care.

More information is available at https://www.senzime.com/pediatric.